Alps Advisors Inc Akero Therapeutics, Inc. Transaction History

Alps Advisors Inc

$17.2 Billion
Q1 2025

A detailed history of Alps Advisors Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 58,305 shares of AKRO stock, worth $2.98 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

58,305

Previous 56,440 3.3%

Holding current value

$2.98 Million

Previous $1.57 Million 50.32%

% of portfolio

0.01%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 30, 2025	BUY	$21.87 - $57.56 $40,787 - $107,349	1,865 Added 3.3%	58,305 $2.36 Million
Q4 2024 Feb 13, 2025	BUY	$26.75 - $35.28 $91,083 - $120,128	3,405 Added 6.42%	56,440 $1.57 Million
Q3 2024 Nov 12, 2024	SELL	$21.45 - $29.34 $19,390 - $26,523	-904 Reduced 1.68%	53,035 $1.52 Million
Q2 2024 Aug 13, 2024	BUY	$18.31 - $24.62 $260,551 - $350,342	14,230 Added 35.84%	53,939 $1.27 Million
Q1 2024 May 14, 2024	BUY	$17.76 - $31.18 $43,991 - $77,232	2,477 Added 6.65%	39,709 $1 Million
Q4 2023 Feb 14, 2024	SELL	$11.38 - $50.33 $42,970 - $190,046	-3,776 Reduced 9.21%	37,232 $869,000
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $14,128 - $17,921	343 Added 0.84%	41,008 $2.07 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $363,403 - $560,324	9,851 Added 31.97%	40,665 $1.9 Million
Q1 2023 May 10, 2023	SELL	$37.27 - $50.24 $33,952 - $45,768	-911 Reduced 2.87%	30,814 $1.18 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $373,758 - $612,499	11,177 Added 54.39%	31,725 $1.74 Million
Q3 2022 Nov 14, 2022	SELL	$10.15 - $34.05 $2,324 - $7,797	-229 Reduced 1.1%	20,548 $700,000
Q2 2022 Aug 11, 2022	SELL	$8.0 - $15.01 $121,656 - $228,257	-15,207 Reduced 42.26%	20,777 $196,000
Q1 2022 May 16, 2022	SELL	$12.97 - $22.26 $56,925 - $97,699	-4,389 Reduced 10.87%	35,984 $511,000
Q4 2021 Feb 09, 2022	SELL	$19.87 - $26.24 $46,813 - $61,821	-2,356 Reduced 5.51%	40,373 $854,000
Q3 2021 Nov 15, 2021	SELL	$18.65 - $25.46 $58,616 - $80,020	-3,143 Reduced 6.85%	42,729 $955,000
Q2 2021 Aug 11, 2021	SELL	$24.81 - $32.35 $420,331 - $548,073	-16,942 Reduced 26.97%	45,872 $1.14 Million
Q1 2021 May 07, 2021	BUY	$24.04 - $34.19 $2,211 - $3,145	92 Added 0.15%	62,814 $1.82 Million
Q4 2020 Feb 03, 2021	BUY	$25.12 - $29.89 $464,041 - $552,157	18,473 Added 41.75%	62,722 $1.62 Million
Q3 2020 Nov 04, 2020	BUY	$30.79 - $39.92 $158,137 - $205,029	5,136 Added 13.13%	44,249 $1.36 Million
Q2 2020 Aug 05, 2020	SELL	$19.25 - $26.76 $246,496 - $342,661	-12,805 Reduced 24.66%	39,113 $975,000
Q1 2020 May 06, 2020	SELL	$12.8 - $27.05 $77,529 - $163,841	-6,057 Reduced 10.45%	51,918 $1.1 Million
Q4 2019 Feb 07, 2020	BUY	$17.37 - $27.27 $1.01 Million - $1.58 Million	57,975 New	57,975 $1.29 Million

Others Institutions Holding AKRO

# of Institutions

270

Shares Held

86M

Call Options Held

1.02M

Put Options Held

823K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.37B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Akero Therapeutics, Inc. Transaction History